**Core tip:** Covert hepatic encephalopathy (CHE) was prevalent in clinically-stable cirrhosis in the tertiary care hospital. A history of overt hepatic encephalopathy (OHE) was the only risk factor for CHE in patients with OHE history, while a high model for end-stage liver disease score was the only risk factor for those without OHE history. Natural history of CHE in the absence of medication intervention included development of complications, persistence or spontaneous resolution of CHE. Triage of patients based on predictors for exacerbation and resolution, rather than the degree of impairment in daily work productivity or quality of life, could make clinical management of CHE more cost-effective.

INTRODUCTION
============

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome that is most commonly associated with decompensated liver cirrhosis and incorporates a spectrum of manifestations that range from mild cognitive impairment to coma. Generally, HE is subdivided into covert HE (CHE, including minimal HE and West-Haven grade I HE) and overt HE (OHE, West-Haven grades II-IV HE)\[[@B1],[@B2]\]. CHE is regarded as the pre-clinical stage of OHE and occurs in 20%-80% of patients with cirrhosis. CHE is associated with increased progression to OHE\[[@B3]-[@B5]\], poor health-related quality of life (HRQOL)\[[@B6],[@B7]\], and high risk for traffic violations and accidents\[[@B8]\]. It is also an independent predictor for death, liver-related complications and hospitalizations\[[@B9]-[@B11]\]. It is more detrimental for patients in manual labor professions (which involve complex occupational operation and driving of machinery) than those with desk jobs (which involve verbal and intellectual skills). Thus, CHE could endanger patients and their coworkers\[[@B12]\]. The decision to treat CHE depends on the degree of impairment in daily work productivity or quality of life of patients\[[@B1],[@B2]\].

Several studies have investigated the natural history of CHE\[[@B3]-[@B5],[@B9]-[@B11],[@B13]-[@B18]\]. However, in these studies, treatment of other cirrhosis complications \[such as antibiotics for infection or gastroesophageal variceal bleeding (GVB), lactulose for constipation, or albumin infusion for ascites or hepatorenal syndrome\] was not restricted. The medication used to treat these complications during follow-up could hinder the occurrence of CHE and underestimate its disadvantages. Furthermore, perhaps not all CHE patients need to be treated. Thus, we hypothesized that CHE can persist or resolve spontaneously without medication intervention in some clinically-stable cirrhotic patients. Therefore, the aims of the present study were: (1) to observe the real natural history of CHE without medication intervention before development of cirrhosis related complications; and (2) to determine predictors for exacerbation and spontaneous resolution (SR) of CHE, in order to explore the therapeutic indications for CHE, based on natural course without medication intervention. Our findings will help CHE patient triage and lead to more precise and cost-effective clinical management.

MATERIALS AND METHODS
=====================

Subjects, study design and ethics
---------------------------------

This was an observational study performed between August, 2014 and November, 2016 at The First Affiliated Hospital of Nanchang University, which is a tertiary care level hospital in China. Ethics approval was obtained from the Ethics Committee of the hospital, and all participants provided written informed consent in accordance with the Helsinki Declaration.

Consecutive cirrhotic patients in the outpatient department of the hospital were screened and included in the study if they were \> 18 and \< 65 years of age and had a clinical, radiological or histological diagnosis of cirrhosis. Exclusion criteria included the following: presence or history of malignancy, including liver cancer; history of transjugular intrahepatic portosystemic stent shunt or shunt surgery; presence of systemic disease, significant head injury, neurological or psychiatric diseases; alcohol or psychoactive medication intake within 6 mo; antibiotics, lactulose, probiotics or L-ornithine-L-aspartate intake or albumin infusion within 6 wk; illiteracy or inability to perform neuropsychometric tests; or refusal to participate in the study. Patients with history of OHE within 6 mo of inclusion were also excluded to ensure total recovery of last OHE occurrence. As patients with resolved OHE may be at a risk for developing CHE, those patients with history of OHE 6 mo before inclusion were included.

OHE history was assessed based on a patient's medical documents of hospitalization before inclusion. Patients were followed prospectively at intervals of 3 mo in the outpatient department of the hospital. Serial psychometric hepatic encephalopathy score (PHES) along with regular clinical and laboratory evaluations were measured at each visit until death, liver transplantation, or a follow-up of 12 mo after initial screening. If the patients did not show up for the 3-mo follow-up, they were tracked by telephone calls from the study staff. The time to death/liver transplantation and the occurrence of the first cirrhosis-related complications requiring hospitalization were recorded. Any medications recommended to treat CHE by established guidelines\[[@B1],[@B2]\], including antibacterial agents, lactulose, probiotics, L-ornithine-L-aspartate and albumin infusion, had not been administered to patients unless necessary. However, these medications were not restricted if patients developed any complications and physicians thought these medications were necessary. In such cases, time to complications were documented. The Child-Pugh classification (CPC) and model for end-stage liver disease (MELD) scoring system were used to evaluate the severity of liver damage. All clinical data and assessment of complications were obtained from interviews or inpatient/outpatient medical documents.

Clinical data documentation and definition of complications
-----------------------------------------------------------

Qualified physicians performed routine physical examinations and documented biochemical blood tests (*i.e*., complete blood count, alanine aminotransferase, total bilirubin, albumin, creatinine, prothrombin time, international normalization ratio), venous ammonia, virological blood tests \[*i.e*., hepatitis B virus (HBV) DNA and hepatitis C virus RNA levels\], and diagnostic imaging (ultrasonography, computed tomography, or magnetic resonance imaging). The etiology of cirrhosis, history of medication use, OHE and severity of ascites were documented.

The complications, which included OHE, gastrointestinal (GI) bleeding, hepatorenal syndrome, infections, primary hepatic carcinoma (PHC) and severe ascites requiring albumin infusion, were documented in mo. OHE was diagnosed clinically on the basis of impaired mental status, as defined by the West Haven Criteria, and impaired neuromotor function (*i.e*., hyperreflexia, rigidity, myoclonus and asterixis) that required initiation of HE-related therapy with or without hospitalization, and had corroboration from a caregiver\[[@B10],[@B19]\]. GI bleeding was evidenced by melena, hematemesis or hematochezia. Infections were defined as bacterial infections, including pneumonia, sepsis with or without identified infectious focus, urinary tract infection, biliary tract infection, central nervous system infection (*i.e*., meningitis or brain abscess), and spontaneous bacterial peritonitis. PHC diagnosis was based on imaging findings or liver biopsy.

Definition of CHE and of its persistence and resolution
-------------------------------------------------------

PHES tests were used to define CHE. All patients underwent PHES tests in one morning session after breakfast in a quiet room without distracting noises. A specially trained medical doctor assisted the enrolled subjects in finishing these tests. Based on the nomograms of healthy volunteers, the PHES tests were described as abnormal if the score was \< -4\[[@B10],[@B20]\]. Persistence of CHE was defined if CHE patients survived and continued having abnormal PHES results until completion of follow up, in the absence of any of above-mentioned complication(s) or liver transplantation. As CHE runs a fluctuating course, CHE SR was defined if patients had normal PHES results for at least 6 mo at regular follow-up visits, in the absence of above-mentioned medications, complications or liver transplantation. Alternate forms of PHES tests (three parallel versions for each test in our study) were used at 3-mo interval visits to eliminate practice learning effects\[[@B21]\].

Sample size determination and statistical analysis
--------------------------------------------------

Based on a previous study, about 38% of CHE patients developed first OHE episode while about 17% of cirrhotic patients without CHE developed OHE\[[@B10]\]. Based on sample size calculations according to established formulas\[[@B22]\], the minimum sample size necessary for the current study was 78 patients in each group. It is reported that the prevalence of CHE in Chinese cirrhotic patients is about 40%. Thus, a minimum of 195 cirrhotic patients were enrolled to statistically compare the incidence of OHE between the CHE group and unimpaired group.

Continuous variables were expressed as mean ± SD. Categorical variables were described as the number and proportion of each category. Rate differences of OHE development, development of the first cirrhosis-related complications requiring hospitalization and death, between patients with and without CHE, were estimated with Kaplan-Meier analysis and log-rank test. If patients did not develop OHE or other complications and survived, "truncated" was described in the Kaplan-Meier curve. In order to determine risk factors for CHE and predictors for the resolution of CHE, potential parameters were included and first analyzed in the univariate analysis. All tested variables with *P* values \< 0.05 were entered into a logistic regression after adjusting for age, sex and level of education. The *χ*^2^ or Fisher's exact test was used for categorical variables. The analysis of variance was performed as appropriate to determine associations for continuous data. All tested variables with *P* values \< 0.05 were entered into a logistic regression after adjusting for age and sex. In order to determine predictors for developing OHE, the first cirrhosis-related complications requiring hospitalization or mortality in CHE patients, potential parameters were analyzed by univariate analysis. All tested variables with *P* values \< 0.05 were entered into a Cox regression after adjusting for age and sex. All statistical analyses were two-tailed at the 5% level. We used the Statistical Package for Social Science (SPSS Inc.; Chicago, IL, United States) to analyze our data.

RESULTS
=======

Clinical characteristics and prevalence of CHE in cirrhotic patients
--------------------------------------------------------------------

A total of 1384 consecutive outpatient cirrhotic patients were screened, and 366 patients (age: 47.2 ± 8.6 years, male: 73.0%, CPC-A: 43.2%, CPC-B: 50.5%, CPC-C: 6.3%, CPC score: 6.9 ± 1.6, MELD score: 15.4 ± 4.4) fulfilled the criteria and were enrolled in the study (Figure [1](#F1){ref-type="fig"}). Patients were followed for a mean of 11.2 ± 1.3 mo. CHE was identified in 131 (35.8%) patients. The clinical characteristics of CHE and the unimpaired group are shown in Table [1](#T1){ref-type="table"}.

###### 

Comparison of baseline characteristics between cirrhotic patients with and without covert hepatic encephalopathy (unimpaired)

                                      **Unimpaired, *n* =235**   **CHE, *n* = 131**   ***P* value**
  ----------------------------------- -------------------------- -------------------- ---------------
  Sex, female/male                    67/168                     32/99                0.40
  Age in yr                           46.3 ± 8.9                 48.8 ± 7.8           0.009
  Cause                                                                               
  HBV-associated                      180 (76.7)                 94 (71.8)            0.31
  HCV-associated                      8 (3.4)                    4 (3.1)              0.86
  Alcohol-associated                  25 (10.6)                  19 (14.5)            0.28
  Others                              22 (9.4)                   14 (10.7)            0.68
  Level of education                                                                  
  Primary school                      34 (14.5)                  45 (34.4)            \< 0.001
  Junior high school                  99 (42.1)                  52 (39.7)            0.65
  Senior high school                  70 (29.8)                  33 (25.2)            0.35
  College degree or above             32 (13.6)                  1 (0.8)              \< 0.001
  Creatinine                          69.0 ± 16.3                71.3 ± 28.0          0.32
  Venous ammonia                      44.3 ± 4.2                 57.9 ± 8.9           \< 0.001
  Albumin                             33.5 ± 7.7                 26.2 ± 6.1           \< 0.001
  High total bilirubin                17.3 ± 12.3                17.0 ± 9.1           0.76
  Platelets, 10^9^/L                  102.6 ± 99.7               98.5 ± 96.7          0.70
  International normalization ratio   1.14 ± 0.12                1.14 ± 0.15          0.99
  Ascites, none/mild/severe           138/65/32                  19/30/82             \< 0.001
  History of OHE                      12 (5.1)                   54 (41.2)            \< 0.001
  CPC, N, A/B/C                       118/111/6                  40/74/17             \< 0.001
  MELD score                          14.6 ± 2.9                 16.9 ± 6.0           0.02

Data are presented as *n*, *n* (%) or mean ± SD. CHE: Covert hepatic encephalopathy; CPC: Child-Pugh classification; HBV: Hepatitis B virus; HCV: Hepatitis C virus; MELD: Model for end-stage liver disease; OHE: Overt hepatic encephalopathy.

![Flow diagram of cirrhotic patients included in the study. CHE: Covert hepatic encephalopathy; OHE: Overt hepatic encephalopathy; TIPS: Transjugular intrahepatic portosystemic stent.](WJG-23-6321-g001){#F1}

Risk factors of CHE in cirrhotic patients
-----------------------------------------

Compared with unimpaired patients, CHE patients were older and had a more frequent OHE history. After adjusting for age, sex and level of education, logistic analysis indicated that a history of OHE (*β*: 2.72, OR *=* 7.18, 95%CI: 3.45-14.92, *P* \< 0.001) was the only risk factor for CHE in patients with OHE history, while a MELD score \> 20 (*β*: 1.71, OR *=* 5.53, 95%CI: 1.33-22.89, *P* = 0.02) was the only risk factor for patients without OHE history.

Complications and mortality in cirrhotic patients
-------------------------------------------------

Among the 366 patients included in this study, 323 (88.3%) completed the follow-up and survived. Twenty-three patients (unimpaired: 18.3% *vs* CHE: 28.2%) died, and 20 patients (unimpaired: 5.1% *vs* CHE: 6.1%) were lost to follow-up. None of the patients developed PHC or underwent liver transplantation during follow-up. The prevalence of cirrhosis-related complications requiring hospitalization and mortality were 28.2% and 11.5% in the CHE group *vs* 18.3% and 4.7% in the unimpaired group, respectively. Patients in the CHE group had higher rates of mortality (*P* = 0.012) and incidence of first cirrhosis-related complications requiring hospitalization (*P* = 0.008), including OHE (*P* \< 0.001), compared to patients in the unimpaired group (Figure [2](#F2){ref-type="fig"}).

![Time from inclusion to development of the first cirrhosis-related complications requiring hospitalization and death for patients with and without covert hepatic encephalopathy. A: Time from inclusion to development of OHE; B: Time from inclusion to development of the first cirrhosis-related complications requiring hospitalization; C: Time from inclusion to death. The Kaplan-Meier curve for estimated cumulative incidence in the Y axis and months from initial entry in the X axis. Log-rank statistics were used to compare groups. CHE: Covert hepatic encephalopathy; OHE: Overt hepatic encephalopathy.](WJG-23-6321-g002){#F2}

Natural history of CHE
----------------------

After 11.2 ± 1.3 mo of follow-up for 131 CHE patients, 108 patients (82.4%) had completed the follow-up and survived. Thirty-seven patients (28.2%) developed cirrhosis-related complications requiring hospitalization, including 23 patients that developed OHE (17.6%). Fifty-five patients (42.0%) suffered persistent CHE, while 26 patients (19.8%) had CHE SR. The comparisons of clinical characteristics between CHE patients with and without OHE development, between those with and without development of the cirrhosis-related complications requiring hospitalization, between those with and without CHE SR, and between survivors *vs* non-survivors during follow-up are shown in Table [2](#T2){ref-type="table"}.

###### 

Comparison of clinical characteristics between 131 covert hepatic encephalopathy patients with and without overt hepatic encephalopathy development, between those with and without development of the first cirrhosis-related complications requiring hospitalization, between those with and without resolution of covert hepatic encephalopathy, and between survivors and non-survivors during follow-up

                              **Development of OHE**   **Complication(s)**   **Death**   **Resolution of CHE**                                                                                                     
  --------------------------- ------------------------ --------------------- ----------- ----------------------- -------------- ---------- ------------- --------------- ---------- --------------- -------------- ----------
  Male sex                    19 (82.6)                80 (74.1)             0.39        33 (89.2)               66 (70.2)      0.02       14 (93.3)     85 (73.3)       0.09       14 (53.8)       85 (81)        0.004
  Age in yr                   46.4 ± 7.9               47.3 ± 8.7            0.56        47.3 ± 8.3              47.2 ± 8.7     0.90       44.7 ± 7.8    47.4 ± 8.6      0.13       47.8 ± 8.2      49.0 ± 7.8     0.48
  HBV-associated              17 (73.9)                77 (71.3)             0.80        27 (73.0)               67 (71.3)      0.85       9 (60)        85 (73.3)       0.28       17 (65.4)       77 (73.3)      0.42
  Creatinine                  80.5 ± 42.7              68.6 ± 16.8           0.001       76.5 ± 33.2             68.0 ± 16.1    0.001      95.3 ± 46.4   67.9 ± 16.6     \< 0.001   72.6 ± 23.7     71.0 ± 29.1    0.80
  Albumin in g/L              27.2 ± 8.1               31.3 ± 7.8            0.003       29.9 ± 7.9              31.1 ± 8.0     0.23       29.0 ± 8.4    31.0 ± 7.9      0.21       27.8 ± 5.3      25.8 ± 6.2     0.13
  Total bilirubin in μmol/L   23.3 ± 16.7              16.5 ± 10.2           \< 0.001    22.5 ± 16.3             15.7 ± 8.9     \< 0.001   29.5 ± 24.0   16.3 ± 9.0      \< 0.001   15.8 ± 10.5     17.2 ± 8.8     0.47
  Platelets, 10^9^/L          62.0 ± 37.2              105.7 ± 102.4         0.009       81.8 ± 105.8            106.6 ± 95.9   0.046      81.3 ± 59.2   102.7 ± 100.8   0.29       131.1 ± 109.2   90.35 ± 92.1   0.05
  INR                         1.2 ± 0.2                1.1 ± 0.1             \< 0.001    1.2 ± 0.1               1.1 ± 0.1      \< 0.001   1.3 ± 0.2     1.1 ± 0.1       \< 0.001   1.1 ± 0.1       1.1 ± 0.2      0.49
  Ascites, none/mild/severe   2/14/2007                12/28/68              0.03        8/21/2008               11/22/61       0.35       1/14/2000     19/29/68        0.03       9/13/2004       15/21/69       0.25
  History of OHE              13 (56.5)                41 (38.0)             0.10        17 (45.9)               37 (39.4)      0.49       12 (80)       42 (36.2)       0.001      3 (11.5)        51 (48.6)      0.001
  CPC, A/B/C                  3/18/2                   37/56/15              0.06        6/23/8                  34/51/9        0.04       7/8/2000      40/67/9         \< 0.001   3/2/2021        19/71/15       \< 0.001
  MELD score                  19.6 ± 4.7               14.9 ± 4.1            \< 0.001    19.2 ± 4.2              14.3 ± 3.8     \< 0.001   23.3 ± 5.0    14.8 ± 3.7      \< 0.001   13.7 ± 4.0      17.7 ± 6.2     0.002
  Complications               23 (100)                 14 (13.0)             \< 0.001    37 (100)                0              \< 0.001   10 (66.7)     27 (23.3)       \< 0.001   0               37 (35.2)      \< 0.001
  OHE                         23 (100)                 0                     \< 0.001    23 (62.2)               0              \< 0.001   7 (46.7)      16 (13.8)       0.002      0               23 (21.9)      \< 0.001
  Mortality                   7 (30.4)                 8 (7.4)               0.002       10 (27.0)               5 (5.3)        \< 0.001   15 (100)      0               \< 0.001   0               15 (14.3)      \< 0.001

Data are presented as *n*, *n* (%) or mean ± SD. CHE: Covert hepatic encephalopathy; CPC: Child-Pugh classification; HBV: Hepatitis B virus; INR: International normalization ratio; MELD: Model for end-stage liver disease; OHE: Overt hepatic encephalopathy.

Cox analysis of all the potential parameters (with *P* values \< 0.05 from the univariate analysis shown in Table [2](#T2){ref-type="table"}) indicated that only serum albumin \< 30 g/L was a predictor for developing OHE. Serum creatinine \> 133 μmol/L, MELD score \> 20 and blood platelet \< 80 × 10^9^/L were predictors for development of the cirrhosis-related complications requiring hospitalization; serum creatinine \> 133 μmol/L was the only predictor for mortality of CHE patients (Table [3](#T3){ref-type="table"}). After adjusting for age and sex, multivariate logistic analysis showed that CPC-B/C (*β*: -2.48, HR = 0.084, 95%CI: 0.026-0.264, *P* \< 0.001) and OHE history (*β*: -1.91, HR = 0.15, 95%CI: 0.03-0.67, *P* = 0.014) were predictors for CHE SR.

###### 

Cox analysis of predictors for developing overt hepatic encephalopathy, the first cirrhosis-related complications requiring hospitalization, and mortality in 131 covert hepatic encephalopathy patients

                                                             **Predictor(s)**    ***β***   **HR**       **95%CI**    ***P* value**
  ---------------------------------------------------------- ------------------- --------- ------------ ------------ ---------------
  For developing OHE                                         Albumin \< 30 g/L   1.65      5.22         1.22-22.32   0.03
  For developing the first cirrhosis-related complications   Cr \> 133 μmol/L    1.24      3.46         1.46-8.20    0.005
  MELD score \> 20                                           2.31                10.12     4.14-24.74   \< 0.001     
  PLT \< 80 × 10^9^/L                                        2.52                2.44      1.69-6.60    0.013        
  For mortality                                              Cr \> 133 μmol/L    1.51      4.75         1.10-20.44   0.036

Cr: Creatinine; MELD: Model for end-stage liver disease; OHE: Overt hepatic encephalopathy; PLT: Platelet.

DISCUSSION
==========

Until now, no study has explored the real natural history of CHE in the absence of medication intervention. Our study shows that CHE can worsen, persist, or even spontaneously resolve without medication intervention over a 1-year period. Patients with an OHE history, low serum albumin, high serum creatinine, decreased blood platelet count, or poor liver function should be treated to prevent complications and reduce mortality. Patients with CPC-A and without OHE history may be monitored with caution without treatment. It is our speculation that triage of CHE patients based on predictors for exacerbation and resolution, rather than on the degree of impairment in daily work productivity or quality of life, will make clinical management more precise and cost-effective.

There are many testing strategies focusing on paper-pencil abnormalities, computerized or neurophysiological tests, such as PHES, repeatable battery for the assessment of neuropsychological status (commonly known as RBANS), inhibitory control test (ICT), EncephalApp Stroop smartphone App, critical flicker frequency (CFF), and electroencephalography (EEG). According to the guidelines, the diagnosis of CHE in multi-center studies should utilize at least two of the current validated testing strategies, consisting of PHES and one of the following: computerized (continuous reaction time, ICT, scan reaction time, or Stroop) or neurophysiological (CFF or EEG).

In single-center or clinical routine studies, investigators should use tests with which they are familiar for assessing the severity of HE, provided that normative reference data are available and the tests have been validated for use in the patient population\[[@B1],[@B2]\]. In this single-center study, we used PHES, which has been previously validated in China\[[@B20]\], to define CHE diagnosis, persistence and resolution. In our study, 35.8% of consecutive clinically stable cirrhotic patients were diagnosed with CHE based on PHES tests, in agreement with previous Chinese studies\[[@B7],[@B20]\].

Only a few studies have discussed risk factors of CHE in cirrhotic patients\[[@B23],[@B24]\]. However, these studies excluded patients with OHE history. As patients with resolved OHE may be at risk for developing CHE, risk factors for patients with OHE history also need to be explored. Yoshimura et al\[[@B25]\] enrolled patients with and without OHE history and revealed that OHE history was strongly associated with CHE, while cirrhosis-related symptom scores were associated with CHE for patients without OHE history, which is similar to our findings.

Several studies have focused on searching for predictors of OHE in cirrhotic patients. A recent study reported that CHE and elevated blood NH~3~ levels contributed to OHE development in cirrhosis\[[@B3]\]. Another study indicated that OHE history, presence of CHE and an albumin level \< 3.5 g/dL were associated with OHE development in cirrhosis\[[@B5]\]. Based on our findings, it is more cost-effective to screen and identify predictors of OHE development in CHE patients rather than in all cirrhotic patients. Our results showed that only serum albumin level \< 30 g/L is the predictor for developing OHE in CHE patients. We propose that CHE patients with a low level of serum albumin should be treated rather than being monitored to reduce hospitalizations and mortality.

Several studies have investigated the natural history of CHE\[[@B3]-[@B5],[@B9]-[@B11],[@B13]-[@B18]\]. Recently, five studies showed that CHE is associated with occurrence of OHE and reduced survival rate\[[@B9]-[@B11],[@B17],[@B18]\]. Thomsen et al\[[@B9]\] enrolled 106 clinically-stable cirrhotic patients with no previous history of OHE and followed them for 230 ± 95 d. They found that 13.3% of CHE patients (defined by CFF, EEG or PHES) developed OHE, and the survival rate was 86.7%. In a multicenter study by Patidar et al\[[@B10]\], a total of 170 cirrhotic patients were followed for a mean of 13 mo. They found that 30% of cirrhotic patients developed at least one OHE episode, and that CHE, which was defined by PHES only, increased their risk of developing OHE, hospitalization and death/transplant despite controlling for MELD.

A study by Ampuero et al\[[@B11]\] demonstrated that patients with CHE, as defined by CFF, had a reduced 5-year survival rate compared to those without CHE (57.4%-68.6% *vs* 70%-82%). It also predicted the occurrence of OHE (37.1%-38.9% in patients with CHE *vs* 18.3%-24.6% in those without CHE). In a multi-center study by Allampati et al\[[@B17]\], a total of 437 cirrhotic patients and 308 controls were followed for 11 mo. The authors reported that 13% of patients developed an episode of OHE, which was predicted by CHE defined by the EncephalApp based on adjusted United States population norms, ICT or PHES.

However, none of the above studies stopped medications used for the treatment of other complications (*i.e*., antibiotics for infection or significant GVB, albumin transfusion for ascites, lactulose for constipation) during follow-up, which can play important roles in preventing occurrence of OHE and help CHE resolution. Persistence and SR of CHE were also not explored in these studies. Therefore, the real natural course of CHE without medication intervention was not evaluated, and therefore the risk of developing complications and mortality in CHE patients could be underestimated due to the medications used during follow-up. Furthermore, though CHE was reported to be associated with a higher risk of developing complications and reduced survival rate in these studies, it remains to be determined if all CHE patients need to be treated.

Our study revealed that CHE can resolve after 3 mo following the initial diagnosis, or can last as long as 1 year in the absence of medication intervention. Predictors for CHE SR were also explored in our study for the first time. Our data indicated that patients with predictors for SR could be monitored without resorting to medications, and receive appropriate medical support if predictors for development of complications and mortality appeared. Our findings also suggested that CHE patients need to be repeatedly evaluated at appropriate time intervals, as CHE can fluctuate over time.

There are some limitations in our study. Firstly, we conducted a single-center observational study with a relatively short follow-up period. However, we are the first to explore the natural history of CHE without medication intervention with a sample size large enough and time period long enough to identify predictors for exacerbation and SR of CHE. In addition, as cirrhotic patients developed complications over time, fewer patients were free of medications at a longer period of follow-up. Then it was of little significance to explore the natural course of CHE due to the limited number of patients. Secondly, a 3-mo interval between visits was arbitrarily decided by the researchers. As CHE and OHE fluctuate and cognitive changes may be missed by this frequency, shorter intervals of observation would have been more convincing. However, it is our opinion that a 3-mo interval is the minimal time interval to eliminate learning effects for PHES. Thirdly, only some of the medications for treating cirrhosis, including antibacterial agents, lactulose, probiotics, L-ornithine-L-aspartate and albumin, were restricted unless necessary. However, some other medications, such as proton pump inhibitors, diuretics, non-selective beta-blocker and anti-HBV agents, were not restricted during our follow-up, as the potential impact of these agents on CHE is still in debate.

In summary, CHE is prevalent in clinically-stable cirrhotic patients and is associated with an increased risk of complications, hospitalizations and mortality. CHE can evolve into OHE, persist or spontaneously resolve without medication intervention within a short period. Although data are lacking regarding the standard management of CHE in clinical practice, we believe triage of patients based on predictors of exacerbation and improvement of CHE in natural history could make clinical management of CHE more precise and cost-effective.
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